Literature DB >> 3134209

Three-year survey of amikacin use and aminoglycoside resistance in a general hospital in Belgium.

R Vanhoof1, J M Hubrechts, H J Nyssen, E Roebben.   

Abstract

The aim of the study was to evaluate the effect of intensive use of amikacin on the resistance levels to amikacin, gentamicin, tobramycin, netilmicin and dibekacin. The base-line resistance in the preamikacin phase (three months of amikacin use less than 1%; 676 isolates) was 1.0% for amikacin, 11.4% for gentamicin, 8.0% tobramycin, 6.2% for netilmicin and 8.3% for dibekacin. During the amikacin phase (36 months of average amikacin use of 89%; 6048 isolates) there was no significant change in aminoglycoside resistance except for dibekacin (from 8.3% to 10.9%, 0.05 greater than p greater than 0.02). Isolated amikacin resistance was not observed.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3134209     DOI： 10.1007/bf01963076

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  14 in total

1.  Resistance surveillance programs and the incidence of gram-negative bacillary resistance to amikacin from 1967 to 1985.

Authors:  D N Gerding; T A Larson
Journal:  Am J Med       Date:  1986-06-30       Impact factor: 4.965

2.  Frequency of aminoglycoside 6'-N-acetyltransferase among Serratia species during increased use of amikacin in the hospital.

Authors:  T A Larson; C R Garrett; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

3.  A one year survey on the epidemiology of aminoglycoside resistance in a general hospital: influence of amikacin.

Authors:  R Vanhoof; J M Hubrechts; E Roebben; M Claeys; E Nulens; H J Nyssen; M Van Haeverbeek; J P Van Gysel
Journal:  Acta Clin Belg       Date:  1986       Impact factor: 1.264

4.  Responsibility of the infectious disease community for optimal use of antibiotics: views of the membership of the Infectious Diseases Society of America.

Authors:  C M Kunin; S Chambers
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug

Review 5.  Problems and changing patterns of resistance with gram-negative bacteria.

Authors:  J F Acar
Journal:  Rev Infect Dis       Date:  1985 Nov-Dec

6.  Progressive increase in antibiotic resistance of gram-negative bacterial isolates. Walter Reed Hospital, 1976 to 1980: specific analysis of gentamicin, tobramycin, and amikacin resistance.

Authors:  A S Cross; S Opal; D J Kopecko
Journal:  Arch Intern Med       Date:  1983-11

7.  Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.

Authors:  R D Moore; P S Lietman; C R Smith
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

8.  Resistance of gram-negative bacilli as related to hospital use of antimicrobial agents.

Authors:  M Y Ma; E J Goldstein; M H Friedman; M S Anderson; M E Mulligan
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

9.  Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center.

Authors:  D N Gerding; T A Larson
Journal:  Am J Med       Date:  1985-07-15       Impact factor: 4.965

10.  Amikacin-resistant gram-negative bacilli: correlation of occurrence with amikacin use.

Authors:  J F Levine; M J Maslow; R E Leibowitz; A A Pollock; B A Hanna; S Schaefler; M S Simberkoff; J J Rahal
Journal:  J Infect Dis       Date:  1985-02       Impact factor: 5.226
View more
  2 in total

1.  Increased resistance to amikacin in a neonatal unit following intensive amikacin usage.

Authors:  I R Friedland; E Funk; M Khoosal; K P Klugman
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

2.  Appearance of amikacin and tobramycin resistance due to 4'-aminoglycoside nucleotidyltransferase [ANT(4')-II] in gram-negative pathogens.

Authors:  G A Jacoby; M J Blaser; P Santanam; H Hächler; F H Kayser; R S Hare; G H Miller
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.